NCT01157559 - Efficacy and Safety With Ziprasidone in First-episode Psychosis | Crick | Crick

Efficacy and Safety With Ziprasidone in First-episode Psychosis

Phase 4CompletedNCT01157559

Chonbuk National University Hospital27 enrolled

Overview

The aim of the study is to investigate the efficacy and safety of ziprasidone in patients with first episode psychosis.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

27

Conditions

First Episode Psychosis

Interventions

ZiprasidoneDRUG

8 week prospective study

Eligibility

Sex: ALLMin age: 14 YearsMax age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who meet DSM-IV criteria for first episode schizophrenia, schizophreniform disorder and schizoaffective disorder Exclusion Criteria: * Patients with previously prescribed antipsychotic medication in 2 weeks or more * patients with substance-induced psychotic disorder, serious suicide attempt, neurological disorder, etc.

Locations (3)

Department of Psychiatry, Chonbuk national University Hospital

Jeonju, South Korea

Heo psychiatric Hospital

Jeonju, South Korea

Jeonju Jesus Hospital

Jeonju, South Korea

Outcomes

Primary Outcomes

Symptoms assessment by objective rating scales

PANSS total score, SANS, clinical global impression scale, GAF

Time frame: week 1

Symptoms assessment by objective rating scales

PANSS total score, SANS, clinical global impression scale, GAF

Time frame: week 2

Symptoms assessment by objective rating scales

PANSS total score, SANS, clinical global impression scale, GAF

Time frame: week 4

Symptoms assessment by objective rating scales

PANSS total score, SANS, clinical global impression scale, GAF

Time frame: week 6

Symptoms assessment by objective rating scales

PANSS total score, SANS, clinical global impression scale, GAF, DAS-S

Time frame: week 8

Secondary Outcomes

Assessment of adverse events by objective rating scales and self report scales

Simpson and Angus rating scale, Barnes Akathisia rating scale and Abnormal Involuntary Movement Scale

Time frame: one-month

Assessment of adverse events by objective rating scales and self report scales

Simpson and Angus rating scale, Barnes Akathisia rating scale and Abnormal Involuntary Movement Scale

Time frame: two-month.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.